A Phase 1 interventional study of Vonsetamig and Odronextamab in Lupus Nephritis (LN), sponsored by Regeneron Pharmaceuticals. Recruiting at 20 sites in 6 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Lupus Nephritis with a site in Spain — 8 open to participants now, 12 under way, 3 of them phase 3. Lupus Nephritis · Spain.
Among the 39 studies in Lupus Nephritis with a site in Spain, this one is the 20th largest by planned enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 1, reaches primary completion later than 7 of the 11 other live ones, and was the 37th registered.
343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.
Browse Lupus Nephritis studies →8 of the 39 studies in Lupus Nephritis with a site in Spain are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Spain
Ages 18–65
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in Spain, United States, Australia and 7 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Spain, United States, Brazil and 15 more countries
Ages 18–100
CRISPR Therapeutics · Sites in Spain, United States, Germany
Ages 18–70
Cabaletta Bio · Sites in Spain, United States, Canada
Ages 12–65
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 19 · Phase 3 14
First in 2004; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 48 across 242 interventional studies indexed under Lupus Nephritis.
Median enrollment 100 across the 37 interventional studies, 92 across the 2 observational. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 39 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 1 study filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
1 of the studies in Lupus Nephritis with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies in Lupus Nephritis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN).
The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up.
This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN.
The study is looking at several other research questions, including:
Key General Inclusion Criteria:
Key General Exclusion Criteria:
NOTE: Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vonsetamig
Drug: Odronextamab
Administered as per the protocol
Also known as: REGN5459
Administered as per the protocol
Also known as: REGN1979
Occurrence of Dose Limiting Toxicities (DLT)
Time frame: Up to 56 days
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Time frame: Through week 76
Severity of TEAEs
Time frame: Through week 76
Proportion of participants no longer receiving a corticosteroid
Time frame: At 6 months
Cumulative total exposure to corticosteroids
Time frame: At 76 weeks
Absolute values of urine Protein-Creatinine Ratio (uPCR)
Time frame: Through week 76
Percent change from baseline of uPCR
Time frame: Through week 76
Absolute values of estimated Glomerular Filtration Rate (eGFR) serum creatinine
Time frame: Through week 76
Percent change from baseline of eGFR serum creatinine
Time frame: Through week 76
Absolute values of blood B-cell counts and other immune cell populations
T cells and Natural Killer (NK) cells
Time frame: Through week 76
Change from baseline of blood B-cell counts and other immune cell populations
T cells and NK cells
Time frame: Through week 76
Absolute values of double-stranded DNA (dsDNA) antibodies
Time frame: Through week 76
Percent change from baseline of dsDNA antibodies
Time frame: Through week 76
Absolute values of anti-Smith antibodies
Time frame: Through week 76
Percent change from baseline of anti-Smith antibodies
Time frame: Through week 76
Absolute values of anti-C1q antibodies
Time frame: Through week 76
Percent change from baseline of anti-C1q antibodies
Time frame: Through week 76
Absolute values of other autoantibodies
anti-nucleosome
Time frame: Through week 76
Percent change from baseline of other autoantibodies
anti-nucleosome
Time frame: Through week 76
Absolute values of Complement Factor C3 (C3) circulating factors
Time frame: Through week 76
Percent change from baseline of C3 circulating factors
Time frame: Through week 76
Absolute values of Complement Factor C4 (C4) circulating factors
Time frame: Through week 76
Percent change from baseline of C4 circulating factors
Time frame: Through week 76
Absolute values of serum levels of Immunoglobulin A (IgA)
Time frame: Through week 76
Percent change from baseline of serum levels of IgA
Time frame: Through week 76
Absolute values of serum levels of Immunoglobulin G (IgG)
Time frame: Through week 76
Percent change from baseline of serum levels of IgG
Time frame: Through week 76
Concentrations of vonsetamig in serum
Time frame: Through week 76
Concentrations of odronextamab in serum
Time frame: Through week 76
Occurence of Anti-Drug Antibodies (ADAs) to vonsetamig
Time frame: Through week 76
Occurence of ADAs to odronextamab
Time frame: Through week 76
Magnitude of ADAs to vonsetamig
Time frame: Through week 76
Magnitude of ADAs to odronextamab
Time frame: Through week 76
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Sep 2029, 44 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vonsetamig · Odronextamab